



Early View

Research letter

The impact of different antibiotic treatment regimens on mortality in *Mycobacterium avium* complex pulmonary disease (MAC-PD): A population-based cohort study

Sarah K. Brode, Hannah Chung, Michael A. Campitelli, Jeffrey C. Kwong, Rinku Sutradhar, Alex Marchand-Austin, Kevin L. Winthrop, Frances B. Jamieson, Theodore K. Marras

Please cite this article as: Brode SK, Chung H, Campitelli MA, *et al.* The impact of different antibiotic treatment regimens on mortality in *Mycobacterium avium* complex pulmonary disease (MAC-PD): A population-based cohort study. *Eur Respir J* 2020; in press (<https://doi.org/10.1183/13993003.01875-2019>).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Title: The impact of different antibiotic treatment regimens on mortality in *Mycobacterium avium* complex pulmonary disease (MAC-PD): A population-based cohort study

Authors/Institutions: Sarah K Brode^{1,2,3,4}, Hannah Chung⁴, Michael A Campitelli⁴, Jeffrey C Kwong^{4,5,6,7,8}, Rinku Sutradhar^{4,7}, Alex Marchand-Austin⁵, Kevin L Winthrop⁹, Frances B Jamieson^{5,10}, and Theodore K Marras^{1,2}

¹Division of Respiriology, Department of Medicine, University of Toronto, Canada

²Department of Medicine, University Health Network and Mount Sinai Hospital, Toronto, Canada

³Division of Respiratory Medicine, West Park Healthcare Centre, Toronto, Canada

⁴ICES, Toronto, Canada

⁵Public Health Ontario, Toronto, Canada

⁶Department of Family and Community Medicine, University of Toronto, Canada

⁷Dalla Lana School of Public Health, University of Toronto, Canada

⁸Centre for Vaccine Preventable Diseases, University of Toronto, Canada

⁹Oregon Health and Science University, Portland OR United States

¹⁰Department of Laboratory Medicine and Pathobiology, University of Toronto, Canada

Support statement: This study was supported by ICES and Public Health Ontario (PHO), which are funded by annual grants from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by ICES, PHO, or the

Ontario MOHLTC is intended or should be inferred. Parts of this material are based on data and/or information compiled and provided by the Canadian Institute of Health Information (CIHI). However, the analyses, conclusions, opinions and statements expressed herein are those of the authors, and not necessarily those of CIHI. We thank IMS Brogan Inc. for use of their Drug Information Database.

To the editor

Evidence-based guidelines recommend the combination of macrolide-ethambutol-rifamycin as first-line treatment for *Mycobacterium avium* complex pulmonary disease (MAC-PD)[1].

Whether this regimen results in improved survival is unknown.

We conducted a retrospective cohort study of older adults treated for MAC-PD using linked laboratory and health administrative databases in Ontario, Canada; these datasets were linked using unique encoded identifiers and analyzed at ICES. We included all Ontario residents aged ≥ 66 years with incident MAC-PD (defined using American Thoracic Society/Infectious Diseases Society of America [ATS/IDSA] microbiological criteria)[1] from 2001-2013 and followed them until December 31, 2014 or death, whichever occurred first. The index date was the date of the first positive culture, and the date of death was captured from the Registered Persons Database. We excluded patients who met ATS/IDSA microbiological criteria for an NTM species other than MAC any time during the study period, and patients who had culture-confirmed TB within 18 months before, and any time after, MAC-PD diagnosis.

We used the Ontario Drug Benefit database to review oral drug claims for antibiotics commonly used to treatment MAC-PD (macrolides, ethambutol, rifamycins, fluoroquinolones, linezolid). Treatment regimens were categorized as: no treatment, macrolide monotherapy, macrolide-ethambutol-rifamycin +/- other antibiotics (regimen group A), macrolide-ethambutol +/- other antibiotics except rifamycins (regimen group B), or another ≥ 2 drug combination (regimen group C). For each patient, information on their treatment regimen was obtained at index date and updated throughout follow-up. Patients had to be dispensed ≥ 180 continuous overlapping days of treatment (either daily or intermittent) for each regimen to qualify. To allow for patients who refilled their prescriptions late, we defined treatment as continuous if the patient

filled their next prescription for the same antibiotic class within 1.5 times the number of days supplied for their last prescription.

We used Cox proportional hazards regression models to compare mortality across treatment regimens. We used statistical contrasts using regression parameter estimates to compare survival of patients receiving regimen group A and regimen group B to patients receiving regimen group C. We hypothesized that these regimens would rank in the following order in terms of superiority and potential survival benefit: $A > B > C$, and modelled antimycobacterial treatment as a 5-level categorical time-varying exposure. The main regression analysis allowed patients to switch arms and contribute follow-up time to a presumably superior regimen (i.e., ‘step-up’) once meeting exposure criteria (i.e., dispensed 180 days of that regimen), after contributing follow-up time to an inferior regimen. However, patients who ‘stepped-down’ to an inferior regimen continued to contribute follow-up time to the most superior regimen they received. In sensitivity analysis 1, we excluded those who ‘stepped-up’ in regimen group. In sensitivity analysis 2, we excluded patients who met exposure criteria for >1 regimen grouping (i.e., ‘stepped-up’ or ‘stepped-down’). In another sensitivity analysis, we limited follow-up to 5 years. As secondary analyses, we contrasted survival of patients receiving regimen groups A, B, and C to no treatment and macrolide monotherapy. The multivariable models were adjusted for demographics and comorbidities (Table 1 footnote) [2-10].

We identified 3148 older Ontarians with incident MAC-PD during the study period. Sustained treatment with ≥ 2 anti-MAC drugs was prescribed to 500 (16%) patients; initial regimens included 163 (33%) group A, 108 (22%) group B, 135 (27%) group C, as well as 94 (19%) who received macrolide monotherapy and later met criteria for regimen groups A, B, or C. We observed no significant differences between groups A, B, and C at baseline in age (mean

75.0, 76.4, and 75.4 years, respectively, $p=0.31$), sex (female 66%, 56%, and 62%, respectively, $p=0.31$), or other baseline characteristics.

In the primary analysis, median time (IQR) from MAC-PD diagnosis to starting treatment was 99 (26-340), 98 (36-357), and 104 (37-312) days for regimen groups A, B, and C respectively. Crude death rates per 1000 person-years (number of deaths) during follow-up were 111.1 (109), 106.3 (49), and 122.4 (50) for regimens A, B, and C, respectively.

Compared to patients treated with regimen group C, we observed no significant differences in unadjusted or adjusted mortality among patients treated with regimen group A or B (Table 1). Patients treated with either regimen group A or B also did not have a significant difference in mortality than patients treated with regimen group C. Sensitivity analyses yielded similar results, though point estimates favored regimen groups A and B. In secondary analyses, patients treated with regimen group A had an increased hazard for adjusted mortality compared to patients receiving no treatment, and there was no significant difference in mortality observed with the other comparisons.

Our observational study did not detect a survival benefit to the guidelines-recommended antibiotic combination compared to an alternative antibiotic regimen. Prior studies of this question are limited. Jenkins *et al.* performed a prospective randomized trial comparing clarithromycin-ethambutol-rifamycin to ciprofloxacin-ethambutol-rifamycin in NTM-PD, including 170 patients with MAC-PD[11]. They found higher mortality in the clarithromycin arm than the ciprofloxacin arm among MAC-PD patients (48% vs 29%), but no differences in mortality among all patients (including those infected with other NTM species) or MAC-PD-specific mortality.

Our study also did not detect a survival benefit to antibiotic treatment when compared to no treatment. However, this comparison likely suffers from confounding by treatment indication. We suspect that treated patients had more severe MAC-PD than untreated patients, but we could not statistically control for disease severity, because we lacked chest imaging results, acid-fast bacilli smear results, and symptom data. Prior single-centre retrospective observational studies that evaluated the association of antibiotic therapy with mortality in MAC-PD, compared to no treatment, found mixed results. Similar to us, Hayashi *et al.* reported that ≥ 2 antibiotics given for ≥ 3 months within 6 months of diagnosis was associated with a slight increase in all-cause mortality in 634 patients, compared to treatment with 0 or 1 antibiotic (HR=1.43, 95%CI 1.01-2.05)[12]. Ito *et al.* found that treatment with ≥ 2 antibiotics given for ≥ 6 months was associated with lower 5-year mortality than no treatment among 164 patients, but the difference was not statistically significant (22% vs. 33%, p=0.30)[13].

Our study has limitations. We defined NTM-PD on microbiologic criteria alone, and therefore may have misclassified some patients as having true disease, perhaps most likely among untreated patients and biasing comparisons with treated patients. We only included adults aged ≥ 66 years, so our findings may not apply to younger patients. We do not have cause of death; this older cohort may have died primarily from causes unrelated to MAC-PD. We were unable to study clofazimine or injectable aminoglycoside usage because this information is not in our databases. Our results may be impacted by confounding by treatment indication; we think this bias explains the higher mortality associated with standard triple therapy compared to no treatment, and may also impact our comparison of different antibiotic regimens, as patients treated with standard triple therapy may have had more severe disease or fewer unmeasured comorbidities than patients treated with other regimens. Finally, we were limited by the small

number of patients treated with a sustained regimen of interest. Frequent adjustments in MAC-PD treatment make studying the effects of a single regimen challenging.

We could not identify an association between survival and antimicrobial drug regimen among patients with MAC-PD. Prospective randomized trials are needed to determine the impact of different antibiotic regimens on mortality.

Table 1. Proportional hazards mortality estimates comparing different antibiotic regimens in MAC-PD

Regimen group comparison	Unadjusted hazard ratio (95% confidence interval)	Adjusted hazard ratio (95% confidence interval)*
Main analysis		
A vs C	0.91 (0.65-1.27)	1.11 (0.79-1.56)
B vs C	0.87 (0.59-1.29)	0.88 (0.59-1.30)
(A or B) vs C	0.93 (0.69-1.26)	1.04 (0.77-1.40)
Sensitivity analysis 1†		
A vs C	0.68 (0.46-1.01)	0.76 (0.51-1.14)
B vs C	0.70 (0.45-1.09)	0.77 (0.49-1.21)
(A or B) vs C	0.69 (0.49-0.99)	0.78 (0.54-1.11)
Sensitivity analysis 2‡		
A vs C	0.75 (0.49-1.14)	0.80 (0.53-1.22)
B vs C	0.73 (0.45-1.19)	0.78 (0.48-1.28)
(A or B) vs C	0.75 (0.52-1.10)	0.82 (0.56-1.20)
Secondary analyses		
A vs no treatment	1.11 (0.91-1.35)	1.26 (1.03-1.54)
B vs no treatment	1.06 (0.79-1.41)	0.99 (0.74-1.33)
C vs no treatment	1.22 (0.92-1.62)	1.13 (0.85-1.50)
A vs macrolide monotherapy	0.71 (0.50-1.01)	0.84 (0.58-1.19)
B vs macrolide monotherapy	0.68 (0.45-1.03)	0.66 (0.4-1.00)
C vs macrolide monotherapy	0.78 (0.52-1.18)	0.75 (0.50-1.14)

Regimen group A: macrolide-ethambutol-rifamycin +/- other antibiotics

Regimen group B: macrolide-ethambutol +/- other antibiotics except for rifamycins

Regimen group C: other ≥ 2 drug combinations

*The multivariable models were adjusted for age, sex, income, rurality, and comorbidities (time-varying adjustment, updated every 6 months or at treatment change) including asthma, chronic kidney disease, chronic obstructive pulmonary disease, diabetes, HIV infection, interstitial lung disease, lung cancer, rheumatoid arthritis, and ACG® System Aggregated Diagnosis Groups (ADGs; a general measure of comorbidity [The Johns Hopkins ACG® System Version 10])[2-10]

†Excluded patients who ‘stepped-up’ in regimen group

‡Excluded patients who ‘stepped-up’ or ‘stepped-down’

References

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Jr., Winthrop K, Subcommittee ATSM, American Thoracic Society, Infectious Disease Society of A. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *American journal of respiratory and critical care medicine* 2007; 175(4): 367-416.
2. Kralj B. Measuring "rurality" for purposes of health-care planning: an empirical measure for Ontario. *Ontario Medical Review* 2000; 10: 33-52.
3. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. *Diabetes Care* 2002; 25(3): 512-516.
4. Widdifield J, Bombardier C, Bernatsky S, Paterson JM, Young J, Green D, Thorne JC, Ivers N, Butt D, Jaakkimainen RL, Wang M, Ahluwalia V, Tomlinson GA, Tu K. Accuracy of Canadian Health Administrative Databases in Identifying Patients with Rheumatoid Arthritis Using a Random Sample of 7500 Patients Seen in Primary Care. *Arthritis Rheum* 2012; 64: S402.
5. Reid RJ, MacWilliam L, Verhulst L, Roos N, Atkinson M. Performance of the ACG case-mix system in two Canadian provinces. *Med Care* 2001; 39(1): 86-99.
6. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying patients with physician-diagnosed asthma in health administrative databases. *Canadian Respiratory Journal* 2009; 16(6): 183-188.

7. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying individuals with physician diagnosed COPD in health administrative databases. *Copd* 2009; 6(5): 388-394.
8. Fleet JL, Dixon SN, Shariff SZ, Quinn RR, Nash DM, Harel Z, Garg AX. Detecting chronic kidney disease in population-based administrative databases using an algorithm of hospital encounter and physician claim codes. *BMC nephrology* 2013; 14: 81.
9. Quinn RR, Laupacis A, Austin PC, Hux JE, Garg AX, Hemmelgarn BR, Oliver MJ. Using administrative datasets to study outcomes in dialysis patients: a validation study. *Med Care* 2010; 48(8): 745-750.
10. Antoniou T, Zagorski B, Loutfy MR, Strike C, Glazier RH. Validation of case-finding algorithms derived from administrative data for identifying adults living with human immunodeficiency virus infection. *PLoS ONE* 2011; 6(6): e21748.
11. Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of *Mycobacterium vaccae* immunotherapy. *Thorax* 2008; 63(7): 627-634.
12. Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with *Mycobacterium avium* complex lung disease. *American journal of respiratory and critical care medicine* 2012; 185(5): 575-583.
13. Ito Y, Hirai T, Maekawa K, Fujita K, Imai S, Tatsumi S, Handa T, Matsumoto H, Muro S, Niimi A, Mishima M. Predictors of 5-year mortality in pulmonary *Mycobacterium avium*-intracellulare complex disease. *The international journal of tuberculosis and lung disease : the*

official journal of the International Union against Tuberculosis and Lung Disease 2012: 16(3):
408-414.